ClinicalTrials.gg
CompletedNCT03338023Updated Mar 29, 2021Results posted

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus

A Phase 3 interventional study of LY2963016 and Lantus® in Type 1 Diabetes, sponsored by Eli Lilly and Company. Completed at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-29.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.

Enrollment
15th of 66
272 · median 73
Started
2018
with 1 other
Phase 3
18 of 66
none open now
Registered
54th of 66
by date
Lead sponsor
4 of 66
Eli Lilly and Company

Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 15th largest by enrollment, is one of 2 that started in 2018, is one of 18 in phase 3, and was the 54th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in combination with mealtime insulin lispro in adult Chinese participants with Type 1 Diabetes Mellitus (T1DM).

03

Conditions studied

  • Type 1 Diabetes

Keywords

  • Insulin Glargine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have T1DM based on the disease diagnostic criteria (World Health Organization [WHO] Classification).
  • Have duration of T1DM ≥1 year.
  • Have ≤11 %.
  • Have been administered with basal-bolus insulins or pre-mixed insulins for at least 90 days prior to screening.
  • Have a (BMI) ≤35 kilograms per meter squared.

Exclusion criteria

Exclusion Criteria:

  • Exposure to an insulin glargine other than Lantus® within previous 30 days.
  • Have had more than one episode of severe hypoglycemia within 6 months prior to entry into the study.
  • Have had more than one episode of diabetic ketoacidosis or emergency room visits for uncontrolled diabetes leading to hospitalization within 6 months prior to entry into the study.
  • Have known or allergy to any of the study insulins (Lantus® or insulin lispro) or to of the study insulins.
  • Are pregnant, intend to become pregnant during the course of the study.
  • Women who are breastfeeding.
  • Are currently taking traditional medicine (herbal medicine or patent medicine) with known/specified content of anti-hyperglycemic effects within 3 months before screening.
  • Have congestive heart failure Class III and IV.
  • Have obvious clinical signs or symptoms, or laboratory evidence, of liver disease.
  • Have any active cancer.
  • Have a history or diagnosis of (HIV) infection.
  • Have presence of gastrointestinal disease.
  • Have a history of renal transplantation, or are currently receiving renal dialysis.
  • Are receiving chronic systemic therapy at pharmacological doses.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
272 participants (actual)

Study arms

  • Experimental
    LY2963016 + Insulin Lispro

    Participants received 100 units per milliliter (U/mL) LY2963016 administered subcutaneously (SC) once daily (QD) and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.

    Drug: LY2963016 · Drug: Insulin Lispro

  • Active comparator
    Lantus® + Insulin Lispro

    Participants received 100 U/mL Lantus® administered SC QD and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.

    Drug: Lantus® · Drug: Insulin Lispro

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus®)

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean was calculated using mixed-effects model for repeated measures (MMRM) with variables baseline HbA1c + Treatment + Pre-study treatment + Pre-study metformin or acarbose usage + Time + Time\*Treatment (Type III sum of squares).

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline in HbA1c (Lantus® Noninferior to LY2963016)

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was calculated using MMRM with variables baseline HbA1c + Treatment + Pre-study treatment + Pre-study metformin or acarbose usage + Time + Time\*Treatment (Type III sum of squares).

    Time frame: Baseline, Week 24

  2. Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values

    The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Before Morning Meal Glucose, 2 Hours After Morning Meal Glucose, Before Mid-Day Meal Glucose, 2 Hours After Mid-Day Meal Glucose, Before Evening Meal Glucose, Bedtime Glucose and 0300 Am Glucose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 24

  3. Percentage of Participants With HbA1c <7%

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.

    Time frame: Week 24

  4. Percentage of Participants With HbA1c ≤6.5%

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.

    Time frame: Week 24

  5. Change From Baseline in Intrapatient Blood Glucose (BG) Variability, Measured by the Standard Deviation of 7-point SMBG

    Change From Baseline in Intrapatient blood glucose (BG). LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 24

  6. Change From Baseline in Glycemic Variability of Fasting Blood Glucose

    Change From Baseline in Glycemic Variability of Fasting Blood Glucose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 24

  7. Change From Baseline in Basal Insulin Dose

    Change from baseline in basal insulin dose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 24

  8. Change From Baseline in Prandial Insulin Dose

    Prandial Insulin Dose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 24

  9. Change From Baseline in Body Weight

    Change from baseline in body weight. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 24

  10. Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ)

    The ITSQ is a validated 22-item questionnaire that was used to assess treatment satisfaction. Items were measured on a 7-point scale, with lower scores reflecting better outcomes. In addition to an overall score, scores were also obtained for 5 domains, including inconvenience of regimen, lifestyle flexibility, glycemic control, hypoglycemic control, and insulin delivery device. Raw domain and overall scores were transformed on a scale from 0 to 100, where a higher score indicated better treatment satisfaction. LS mean was calculated using ANCOVA with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment (Type III sum of squares).

    Time frame: Baseline, Week 24

  11. Number of Participants With Detectable Anti-Glargine Antibodies

    Number of participants with detectable anti-glargine antibodies

    Time frame: Baseline through Week 24

  12. Rate of Documented Symptomatic Hypoglycemia

    Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of ≤70 mg/dL (3.9 mmol/L). The overall yearly rates (events/participant/year) of those hypoglycemic events, calculated as, for each participant, the number of episodes times 365.25 and then divided by the participants treatment duration, will be summarized, and analyzed by a Negative-binomial regression model with treatment as fixed effects and log of (patient's treatment duration/365.25) as an offset variable.

    Time frame: Baseline through Week 24

07

Results

Posted Mar 29, 2021

Participant flow

Participant flow — Overall Study
MilestoneLY2963016 + Insulin LisproLantus® + Insulin Lispro
Started137135
Received at least one dose of study drug137135
Completed128125
Not completed910
Withdrew: Withdrawal by subject34
Withdrew: Protocol violation33
Withdrew: Lost to follow-up21
Withdrew: Physician decision12

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus®)

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean was calculated using mixed-effects model for repeated measures (MMRM) with variables baseline HbA1c + Treatment + Pre-study treatment + Pre-study metformin or acarbose usage + Time + Time\*Treatment (Type III sum of squares).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus®)
Percentage of HbA1cLY2963016 + Insulin LisproLantus® + Insulin Lispro
Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus®)-0.20 ± 0.071-0.08 ± 0.071
Statistical analysis
  • Lantus® + Insulin Lispro · Mean difference (net): -0.12 · 95% CI -0.32 to 0.08
SecondaryChange From Baseline in HbA1c (Lantus® Noninferior to LY2963016)

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was calculated using MMRM with variables baseline HbA1c + Treatment + Pre-study treatment + Pre-study metformin or acarbose usage + Time + Time\*Treatment (Type III sum of squares).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in HbA1c (Lantus® Noninferior to LY2963016)
Percentage of HbA1cLY2963016 + Insulin LisproLantus® + Insulin Lispro
Change From Baseline in HbA1c (Lantus® Noninferior to LY2963016)-0.20 ± 0.071-0.08 ± 0.071
Statistical analysis
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Mean difference (net): -0.12 · 95% CI -0.32 to 0.08
SecondaryChange From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values

The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Before Morning Meal Glucose, 2 Hours After Morning Meal Glucose, Before Mid-Day Meal Glucose, 2 Hours After Mid-Day Meal Glucose, Before Evening Meal Glucose, Bedtime Glucose and 0300 Am Glucose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values
milligrams per deciliter (mg/dL)LY2963016 + Insulin LisproLantus® + Insulin Lispro
Before Morning Meal Glucose-7.2 ± 3.64-0.4 ± 3.68
2 Hours After Morning Meal Glucose-10.6 ± 4.77-2.8 ± 4.83
Before Mid-Day Meal Glucose-4.6 ± 4.138.5 ± 4.21
2 Hours After Mid-Day Meal Glucose-1.6 ± 4.761.9 ± 4.76
Before Evening Meal Glucose-6.2 ± 4.784.8 ± 4.85
Bedtime Glucose-0.4 ± 4.995.0 ± 5.06
0300 Am Glucose-4.9 ± 3.872.5 ± 3.94
Statistical analysis
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Mixed Models Analysis · p = 0.191 · Mean difference (net): -6.8 · 95% CI -17.0 to 3.4
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Mixed Models Analysis · p = 0.250 · Mean difference (net): -7.8 · 95% CI -21.2 to 5.5
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Mixed Models Analysis · p = 0.028 · Mean difference (net): -13.1 · 95% CI -24.7 to -1.5
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Mixed Models Analysis · p = 0.599 · Mean difference (net): -3.6 · 95% CI -16.8 to 9.7
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Mixed Models Analysis · p = 0.109 · Mean difference (net): -11.0 · 95% CI -24.4 to 2.5
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Mixed Models Analysis · p = 0.452 · Mean difference (net): -5.4 · 95% CI -19.4 to 8.6
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Mixed Models Analysis · p = 0.180 · Mean difference (net): -7.4 · 95% CI -18.3 to 3.5
SecondaryPercentage of Participants With HbA1c <7%

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <7%
percentage of participantsLY2963016 + Insulin LisproLantus® + Insulin Lispro
Percentage of Participants With HbA1c <7%30.732.8
Statistical analysis
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Fisher Exact · p = 0.787
SecondaryPercentage of Participants With HbA1c ≤6.5%

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c ≤6.5%
percentage of participantsLY2963016 + Insulin LisproLantus® + Insulin Lispro
Percentage of Participants With HbA1c ≤6.5%15.722.4
Statistical analysis
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Fisher Exact · p = 0.201
SecondaryChange From Baseline in Intrapatient Blood Glucose (BG) Variability, Measured by the Standard Deviation of 7-point SMBG

Change From Baseline in Intrapatient blood glucose (BG). LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in Intrapatient Blood Glucose (BG) Variability, Measured by the Standard Deviation of 7-point SMBG
mg/dLLY2963016 + Insulin LisproLantus® + Insulin Lispro
Change From Baseline in Intrapatient Blood Glucose (BG) Variability, Measured by the Standard Deviation of 7-point SMBG-2.9 ± 1.33-2.6 ± 1.34
Statistical analysis
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Mixed Models Analysis · p = 0.885 · Mean difference (net): -0.3 · 95% CI -0.4 to 3.4
SecondaryChange From Baseline in Glycemic Variability of Fasting Blood Glucose

Change From Baseline in Glycemic Variability of Fasting Blood Glucose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in Glycemic Variability of Fasting Blood Glucose
mg/dLLY2963016 + Insulin LisproLantus® + Insulin Lispro
Morning Pre-meal Standard Deviation-9.0 ± 2.53-5.5 ± 2.56
Daily Mean Standard Deviation-10.4 ± 1.69-8.6 ± 1.71
Statistical analysis
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Mixed Models Analysis · p = 0.328 · Mean difference (net): -3.5 · 95% CI -10.6 to 3.6
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Mixed Models Analysis · p = 0.467 · Mean difference (net): -1.7 · 95% CI -6.5 to 3.0
SecondaryChange From Baseline in Basal Insulin Dose

Change from baseline in basal insulin dose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Units per Day (U/day)
Change From Baseline in Basal Insulin Dose
Units per Day (U/day)LY2963016 + Insulin LisproLantus® + Insulin Lispro
Change From Baseline in Basal Insulin Dose0.7 ± 0.331.5 ± 0.33
Statistical analysis
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Mixed Models Analysis · p = 0.090 · Mean difference (net): -0.8 · 95% CI -1.7 to 0.1
SecondaryChange From Baseline in Prandial Insulin Dose

Prandial Insulin Dose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · U/day
Change From Baseline in Prandial Insulin Dose
U/dayLY2963016 + Insulin LisproLantus® + Insulin Lispro
Change From Baseline in Prandial Insulin Dose0.2 ± 0.491.4 ± 0.50
Statistical analysis
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Mixed Models Analysis · p = 0.089 · Mean difference (net): -1.2 · 95% CI -2.6 to 0.2
SecondaryChange From Baseline in Body Weight

Change from baseline in body weight. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Body Weight
kilograms (kg)LY2963016 + Insulin LisproLantus® + Insulin Lispro
Change From Baseline in Body Weight0.8 ± 0.210.9 ± 0.22
Statistical analysis
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · Mixed Models Analysis · p = 0.770 · Mean difference (net): -0.1 · 95% CI -0.7 to 0.5
SecondaryChange From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ)

The ITSQ is a validated 22-item questionnaire that was used to assess treatment satisfaction. Items were measured on a 7-point scale, with lower scores reflecting better outcomes. In addition to an overall score, scores were also obtained for 5 domains, including inconvenience of regimen, lifestyle flexibility, glycemic control, hypoglycemic control, and insulin delivery device. Raw domain and overall scores were transformed on a scale from 0 to 100, where a higher score indicated better treatment satisfaction. LS mean was calculated using ANCOVA with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment (Type III sum of squares).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ)
score on a scaleLY2963016 + Insulin LisproLantus® + Insulin Lispro
ITSQ Inconvenience of Regimen Transformed Score3.5 ± 1.303.8 ± 1.29
ITSQ Lifestyle Flexibility Transformed Score1.3 ± 1.862.0 ± 1.86
ITSQ Hypoglycemic Control Transformed Score3.2 ± 1.393.8 ± 1.38
ITSQ Glycemic Control Transformed Score6.9 ± 1.646.0 ± 1.64
ITSQ Insulin Delivery Device Satisfaction Transformed Score3.3 ± 1.262.9 ± 1.26
ITSQ Total Transformed Score3.3 ± 1.104.1 ± 1.10
Statistical analysis
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · ANCOVA · p = 0.879 · Mean difference (net): -0.3 · 95% CI -3.9 to 3.3
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · ANCOVA · p = 0.788 · Mean difference (net): -0.7 · 95% CI -5.9 to 4.5
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · ANCOVA · p = 0.775 · Mean difference (net): -0.6 · 95% CI -4.5 to 3.3
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · ANCOVA · p = 0.681 · Mean difference (net): 1.0 · 95% CI -3.6 to 5.6
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · ANCOVA · p = 0.819 · Mean difference (net): 0.4 · 95% CI -3.1 to 3.9
  • LY2963016 + Insulin Lispro vs Lantus® + Insulin Lispro · ANCOVA · p = 0.605 · Mean difference (net): -0.8 · 95% CI -3.9 to 2.3
SecondaryNumber of Participants With Detectable Anti-Glargine Antibodies

Number of participants with detectable anti-glargine antibodies

Time frame:
Baseline through Week 24
Reported as:
Count of participants · Participants
Number of Participants With Detectable Anti-Glargine Antibodies
ParticipantsLY2963016 + Insulin LisproLantus® + Insulin Lispro
Detectable Anti-Glargine Antibodies7668
Detectable Cross Reactive Insulin Antibodies6758
Treatment Emergent Antibody Response (TEAR)4235
SecondaryRate of Documented Symptomatic Hypoglycemia

Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of ≤70 mg/dL (3.9 mmol/L). The overall yearly rates (events/participant/year) of those hypoglycemic events, calculated as, for each participant, the number of episodes times 365.25 and then divided by the participants treatment duration, will be summarized, and analyzed by a Negative-binomial regression model with treatment as fixed effects and log of (patient's treatment duration/365.25) as an offset variable.

Time frame:
Baseline through Week 24
Reported as:
Least squares mean · events/participant/year
Rate of Documented Symptomatic Hypoglycemia
events/participant/yearLY2963016 + Insulin LisproLantus® + Insulin Lispro
Rate of Documented Symptomatic Hypoglycemia12.6 ± 2.4214.0 ± 2.64

Adverse events

Collected over Baseline Up To 28 Weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2963016 + Insulin Lispro0/137 (0%)9/137 (6.6%)84/137 (61.3%)
Lantus® + Insulin Lispro0/135 (0%)8/135 (5.9%)77/135 (57%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventLY2963016 + Insulin LisproLantus® + Insulin Lispro
HypoglycaemiaMetabolism and nutrition disorders2/1373/135
PneumoniaInfections and infestations0/1372/135
Ovarian disorderReproductive system and breast disorders1/770/66
GastroenteritisInfections and infestations1/1371/135
Urinary tract infectionInfections and infestations0/1371/135
Spinal fractureInjury, poisoning and procedural complications0/1371/135
Diabetic ketoacidosisMetabolism and nutrition disorders1/1371/135
NephritisRenal and urinary disorders0/1371/135
PerinephritisRenal and urinary disorders0/1371/135
UreterolithiasisRenal and urinary disorders1/1371/135
Most frequent other events
Showing 10 of 48
Most frequent other events
EventLY2963016 + Insulin LisproLantus® + Insulin Lispro
Upper respiratory tract infectionInfections and infestations34/13723/135
NasopharyngitisInfections and infestations12/13714/135
Injection site painGeneral disorders4/1377/135
DiarrhoeaGastrointestinal disorders7/1373/135
ToothacheGastrointestinal disorders2/1376/135
Urinary tract infectionInfections and infestations5/1372/135
CoughRespiratory, thoracic and mediastinal disorders5/1373/135
GastroenteritisInfections and infestations0/1374/135
PharyngitisInfections and infestations1/1374/135
Weight increasedInvestigations4/1374/135

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)LY2963016 + Insulin LisproLantus® + Insulin LisproTotal
Mean41.8 ± 15.041.4 ± 13.841.6 ± 14.4
Sex: Female, Male
Sex: Female, Male(Participants)LY2963016 + Insulin LisproLantus® + Insulin LisproTotal
Female7766143
Male6069129
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LY2963016 + Insulin LisproLantus® + Insulin LisproTotal
Hispanic or Latino000
Not Hispanic or Latino137135272
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY2963016 + Insulin LisproLantus® + Insulin LisproTotal
American Indian or Alaska Native000
Asian137135272
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)LY2963016 + Insulin LisproLantus® + Insulin LisproTotal
China137135272
Hemoglobin A1c (HbA1c) at Baseline
Hemoglobin A1c (HbA1c) at Baseline(Percentage of HbA1c)LY2963016 + Insulin LisproLantus® + Insulin LisproTotal
Mean7.90 ± 1.327.85 ± 1.487.88 ± 1.40
Duration of Diabetes in years
Duration of Diabetes in years(years)LY2963016 + Insulin LisproLantus® + Insulin LisproTotal
Mean10.29 ± 9.5310.53 ± 9.5310.41 ± 9.51
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per meter square (kg/m²))LY2963016 + Insulin LisproLantus® + Insulin LisproTotal
Mean21.90 ± 2.5422.03 ± 2.3221.96 ± 2.43
08

Study locations

20 sites
  • Peking University Peoples Hospital
    Beijing, Beijing 100044, China
  • Shantou University Medical College No.2 Affiliated Hospital
    Shantou, Guang Dong Province 515041, China
  • Guangdong Province People's Hospital
    Guangzhou, Guangdong 510080, China
  • The First Affiliated Hospital, Sun-Yat Sen University
    Guangzhou, Guangdong 510080, China
  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong 510120, China
  • The 1st Affiliated Hospital of Henan Science and technology
    Luoyang, Henan 471003, China
  • Wu Han Tongji Hospital
    Wu Han, Hu Bei 430030, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Changzhou No.2 People's Hospital
    Changzhou, Jiangsu 213003, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210012, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212001, China
  • No.2 Hospital Affiliated to Jilin University
    Changchun City, Jilin 130041, China
  • Dalian Med. Univ. No 2 Affiliate Hospital
    Dalian, Liao Ning 116023, China
  • The First Affiliated Hospital with Nanjing Medical Universit
    Nanjing, Nanjing 210029, China
  • Shanghai Tenth People's Hospital
    Shanghai, Shanghai 200072, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • First People's Hospital of Yunnan Province
    Kunming, Yunnan 650034, China
  • Peking Union Medical College Hospital
    Beijing, 88798, China
  • Shanghai Putuo District Center Hospital
    Shanghai, 200062, China
09

References and documents

Publications

  • Yan X, Feng C, Lou Y, Zhou Z. Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus(R)): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial. Diabetes Ther. 2022 Jun;13(6):1161-1174. doi: 10.1007/s13300-022-01262-8. Epub 2022 Apr 26. PubMed 35471721 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and asigned data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Mar 2020, 23 months.

Results were first posted in Mar 2021, 1 year after primary completion.

Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 23 months is above that.

Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2017
First posted
Nov 9, 2017
StartActual
Mar 23, 2018
Primary completionActual
Mar 5, 2020
CompletionActual
Mar 5, 2020
Results first posted
Mar 29, 2021
Last update
Mar 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03338023
Responsible party
Sponsor
First posted
Nov 9, 2017
Start date
Mar 23, 2018
Primary completion
Mar 5, 2020
Completion
Mar 5, 2020
Results posted
Mar 29, 2021
Last update
Mar 29, 2021

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion